Nonalcoholic Steatohepatitis Therapeutics Market1

Nonalcoholic Steatohepatitis
Therapeutics Market to Reach US$20.27
bn by 2025, Elafibranor Projected to
Spur Growth
According to a new market report published by Transparency
Market Research “Nonalcoholic Steatohepatitis Therapeutics
Market - Global Industry Analysis, Size, Share, Growth, Trends,
and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis
(NASH) therapeutics market is anticipated to expand at a CAGR
of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.
There are a few key causes of a fatty liver, one of which is nonalcoholic
fatty liver disease. It occurs when excessive alcohol
consumption causes large deposits of fat in the liver. It is one of
the most commonly linked diseases to alcoholism and also one
of the most commonly found liver disorders in developed
economies. Non-alcoholic fatty liver disease (NAFLD) is caused
by reasons linked to metabolic issues and insulin resistance.
Obesity is another factor that can significantly increase the
chances of contracting NAFLD.
According to the National Health and Nutrition Examination
Survey, the rate of NAFLD in the U.S. within 2011 and 2012
was nearly 30%. In cases where NAFLD was not detected in
time and reached higher levels of complications, non-alcoholic

steatohepatitis (NASH) can occur. It is the most extreme form of
non-alcoholic fatty liver disease and is a direct causative factor
for liver cirrhosis. NAFLD by itself can be treated successfully
if detected in time. NASH, on the other hand, needs special care.
Browse Full Research Report on Nonalcoholic
Steatohepatitis Therapeutics Market:
http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html
The global non-alcoholic steatohepatitis therapeutics market is
expected to reach US$20.2 bn by the end of 2025. It is
expanding at a CAGR of 10.70% between 2015 and 2025. The
key players in this market that are expected to play a major role
in the market’s immediate future include Tobira Therapeutics,
Inc., Conatus Pharmaceuticals, Immuron Ltd., Zydus Cadila,
Gilead Sciences, Inc., GENFIT SA, Galmed Pharmaceuticals
Ltd., Intercept Pharmaceuticals Inc., and Astazeneca Plc.
Elafibranor Propels Global NASH Market
The major segments of the market by drug type include
Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and
potential drug candidates in phase III. Elafibranor is expected to
lead the market in the near future by being the largest and fastest
growing segment of the global non-alcoholic steatohepatitis

therapeutics market. Elafibranor is currently the most advanced
and most effective drug in this market and is expected to exhibit
the highest CAGR of all the various drug types.
There are no treatments that are specifically used for nonalcoholic
steatohepatitis. Apart from the various drugs used for
the treatment of fatty liver, doctors often suggest the patient to
start losing weight if they are overweight. Other suggestions
given include completely avoiding alcohol, consuming a
balanced diet, and increasing physical activity.
NASH and NAFLD Linked to Obesity
Medical records are pointing to an increasing prevalence of
NAFLD and NASH across the world. However, these issues are
more common in developed economies such as North America.
This is due to the larger percentage of the obese population in
the total population in developed regions than others. The global
non-alcoholic steatohepatitis therapeutics market is, therefore,
developing at a higher rate in countries such as the U.S., owing
to the higher demand for NASH and NAFLD treatment options.
The healthcare industry in these regions is taking fatty liver
complications a lot more seriously. In the recent past, the

number of obese adults and children in the U.S. have doubled
and tripled, respectively. This is a major issue, as obese patients
who suffer from NFALD or NASH are also likely to suffer from
high blood cholesterol and diabetes.
Apart from obesity, patients of glucose intolerance and
dyslipidemia are also prone to suffer from NFALD and NASH.
There is no clear link that points to the reason NFALD occurs,
but it is currently suggested that insulin resistance has a major
role to play in it. In spite of the severity of the disease, patients
are largely asymptomatic until complications arise. Therefore,
the best preventive measure against NFALD and NASH is to
lead a healthy life and moderate alcohol consumption.
Browse Full Press Release on Nonalcoholic Steatohepatitis
Therapeutics Market:
Press Release
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data

sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com